Trials / Completed
CompletedNCT03006159
A Phase 1, Randomized, Placebo-controlled, Multiple Dose Escalation Study to Investigate Safety, Pharmacokinetics, and Pharmacodynamics of SHR0534 in Chinese Type 2 Diabetic Patients
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, placebo-controlled, multiple dose escalation study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR0534. The study will be conducted with dose of 5 mg, 10mg and 25 mg. Chinese Type 2 Diabetic patients will be randomized in each cohort to receive the study drug or placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR0534 | |
| DRUG | Placebo |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2015-12-01
- Completion
- 2016-03-01
- First posted
- 2016-12-30
- Last updated
- 2016-12-30
Source: ClinicalTrials.gov record NCT03006159. Inclusion in this directory is not an endorsement.